Risks of Vision Loss Linked to GLP-1 Diabetes Drugs
Recent studies on semaglutide, a GLP-1 medication, show conflicting results regarding its link to eye problems. While some research suggests a possible association with nonarteritic anterior ischemic optic neuropathy (NAION), overall evidence is inconclusive, and the medication appears not to significantly increase the risk of diabetic retinopathy or other eye disorders. Experts recommend ongoing research and regular eye exams for users.